Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease. - Wikidata - awgldk - TriplyDB

Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

http://www.wikidata.org/entity/Q30407860

about

Updates in hyperkalemia: Outcomes and therapeutic strategies.Association of incident obstructive sleep apnoea with outcomes in a large cohort of US veterans.Observational modeling of strict vs conventional blood pressure control in patients with chronic kidney disease.Renin-Angiotensin System Inhibitor is Associated with Lower Risk of Ensuing Chronic Kidney Disease after Functional Recovery from Acute Kidney Injury.Dose of hemodialysis and survival: a marginal structural model analysis Comparative Effectiveness of Renin-Angiotensin System Antagonists in Maintenance Dialysis Patients.The role of genetic polymorphisms of the Renin-Angiotensin System in renal diseases: A meta-analysis Association of medical treatment nonadherence with all-cause mortality in newly treated hypertensive US veterans Association of hepatitis C viral infection with incidence and progression of chronic kidney disease in a large cohort of US veterans.Acute Kidney Injury After Major Surgery: A Retrospective Analysis of Veterans Health Administration Data.Association of age and BMI with kidney function and mortality: a cohort study.Blood pressure and proteinuria control remains a challenge in patients with type 2 diabetes mellitus and chronic kidney disease: experience from the prospective observational ALICE-PROTECT study.Impact of Non-Adherence on Renal and Cardiovascular Outcomes in US Veterans Association of Pre-Operative Albuminuria with Post-Operative Outcomes after Coronary Artery Bypass Grafting.Association of incident restless legs syndrome with outcomes in a large cohort of US veterans Age and Outcomes Associated with BP in Patients with Incident CKD.Cardiovascular disease in patients with chronic kidney disease: a neglected subgroup.Management of hyperkalaemia in chronic kidney disease.Control of hypertension and survival in haemodialysis patients.A review of the benefits of Satureja species on metabolic syndrome and their possible mechanisms of action.Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in women of childbearing age: risks versus benefits.Kidney dysfunction and left ventricular assist device support: a comprehensive perioperative review.The Effect of Renin-angiotensin System Inhibitors on Kidney Allograft Survival: A Systematic Review and Meta-analysis.Race, Serum Potassium, and Associations With ESRD and Mortality.Angiotensin-converting enzyme inhibitors and receptor blockers in heart failure and chronic kidney disease - Demystifying controversies.Pain and Kidney Function Decline and Mortality: A Cohort Study of US Veterans.Heart Failure Increases the Risk of Adverse Renal Outcomes in Patients With Normal Kidney Function.Candidate Surrogate End Points for ESRD after AKI.The effect of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker use on mortality in patients with chronic kidney disease: a meta-analysis of observational studies.Increased Risk of Incident Chronic Kidney Disease, Cardiovascular Disease, and Mortality in Patients With Diabetes With Comorbid Depression.Annual all-cause mortality rate for patients with diabetic kidney disease in Singapore.Renin-Angiotensin-Aldosterone System Blockers in Elderly Adults with Chronic Kidney Disease without Diabetes Mellitus or Proteinuria.Treatment effects of renin-angiotensin aldosterone system blockade on kidney failure and mortality in chronic kidney disease patients.Effects of cilostazol and renin-angiotensin system (RAS) blockers on the renal disease progression of Korean patients: a retrospective cohort study.The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients.Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease.Construction, Enzyme Response, and Substrate Capacity of a Hyaluronan-Cyclodextrin Supramolecular Assembly.Blood HER2 and Uromodulin as Causal Mediators of CKD.Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers for Geriatric Ischemic Stroke Patients: Are the Rates Right?

P2860

Q30245585-E1D67D2C-903B-4970-988C-8C9E7EA73088 Q30279244-73456447-F641-4FC1-8EAB-B6AFCBB6F223 Q30407790-96D142C4-1183-4820-B4D1-F511A6D486AC Q33559888-4489D490-439C-4179-B0CC-C070D87F8845 Q33723192-3EF95FD8-5380-42E7-B92F-1E71A66034F3 Q33730477-0AC84D3E-068B-45D2-B664-2194ECED02CD Q34121179-C97441C1-8C37-48D9-97C6-B05B03578F18 Q34315403-FA663DCA-9365-4130-8DCB-B10ABD48D991 Q35528192-48A9F91D-F9E1-4A98-A8FD-192E81152E22 Q35763952-23C8B12C-DB00-4370-913D-BC49E279EB2B Q35991609-D5FB8DB9-2FD7-4141-B685-4BA38B5454BE Q36140152-A340D1A1-37FB-4E9F-8DCC-788A38844470 Q36148339-538379D9-330C-4AE0-9DCE-7761E6B5D377 Q36262671-8DAA5F03-BE7E-4C70-A551-F0842A010E0D Q36698149-82CEDD9F-9134-45C3-9FFA-367DA5F271B8 Q36874551-82073823-D71B-452E-AE27-75610516A66F Q37463969-E643A0A8-8CD3-4126-A72B-9986BE31B021 Q38249892-803E4AF8-97B3-48A4-A7FC-01A209899F24 Q38265708-F032340A-59E2-4E2E-826E-26FB83766A81 Q38309138-D7BA7559-B801-4742-A910-E7CD25B7338C Q38328807-6AF01B98-D8E0-4068-8CE8-0E091F8B32D4 Q38373349-BA578501-430E-4D21-9326-0499F32ACDF8 Q38825505-667B36C3-A59A-456A-BE8C-FB75151CBA57 Q38864040-2709F174-625C-4794-BD0A-5F934E5EE5EB Q39397039-4C1BD9F7-4A95-46F8-876E-6FF951FE1C17 Q39827435-7342234F-BA51-45C7-BDFC-95CAD1191519 Q40098944-0293EF4A-02CE-447E-A0EA-715C7D1D7D96 Q40921568-520F7008-E82E-4BE0-92BC-0947D6C55BBE Q40965170-BD566F51-3041-4D78-94AF-967A091A7DFE Q42664906-FB251F23-9B63-488F-9B3E-D9998F9432F5 Q43935435-C837BF5F-7CA9-48FE-9AE2-D1A1B81C9788 Q45023857-84A564FE-7FEA-42CA-BAB0-E1517D3BE56C Q47153972-5307EFC8-6B4A-4D8A-B80C-24DFE442999D Q47761508-29328843-01F2-450A-B780-C382182238AE Q48301048-CAB8C891-E2CC-42F0-9077-AF9858F12717 Q50154733-B01F70CA-7739-4F4A-8A2B-31D7EF42E4BD Q51650321-644D8B8D-E93B-449F-A79B-A3E911909018 Q51743726-5E4572C6-5CE4-4EB4-8C37-25D0F17D8EB7 Q53561964-03F5B2EC-0E35-4703-B7FF-30024671356F Q55433025-7C81AC57-3EF6-466E-B07D-903F539D51EE

P2860

Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease.

http://www.wikidata.org/entity/Q30407860

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@ast

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@en

type

label

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@ast

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@en

prefLabel

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@ast

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@en

P1433

Q30407860-5C2F1845-285B-461F-94F3-8D23708F41CD

P1476

Q30407860-7CDBD435-D4BB-4D46-8097-1A5800A5E26F

P2093

Q30407860-2B58786D-75AC-45F6-AA6D-0F75B655B359

Q30407860-95F68DE8-CA0E-41CB-8E20-F287AB02306C

Q30407860-CC24F04F-850B-4345-94A3-1C0D5A07B019

Q30407860-DCEC9641-5817-4922-B77D-EDA6447A0CE6

P2860

Q30407860-03C63A90-A451-4DF8-BD10-2B6D4E7D35A6

Q30407860-03F49366-DC7F-4C83-9D95-DB8077E2858B

Q30407860-0798C120-E2F5-41D0-9221-E30EB675466B

Q30407860-0B57D564-04A1-4254-810B-610A75D373D4

Q30407860-0D6856E7-774D-4121-A9AE-73B8C6FD7797

Q30407860-13E71174-2704-4174-8209-2CB67CBF1609

Q30407860-1CA2A41A-041A-4663-B800-E776209EF9BB

Q30407860-1EEC6616-7EEB-4519-9A90-AD587180D86C

Q30407860-20326FB5-0E40-4E50-BF27-57D1E1B0A515

Q30407860-2584CC97-2D17-42D2-A574-D30D6331128A

P304

Q30407860-59131D5E-DAA6-439D-9F9C-247626D62E4E

P31

Q30407860-3AC29EC7-EB69-4246-9308-B4BA1FB802C7

P356

Q30407860-931CA3C1-7B4B-448E-9CA6-6BADF7A97D36

P407

Q30407860-BFB5359A-CA4D-4AE8-A440-723530CFA82A

P433

Q30407860-C3613BBF-F7CF-4CEB-B573-E8A8C72655B4

P478

Q30407860-BB3C9CBF-0D8B-4E47-AADE-185C51ADD897

P50

Q30407860-05213825-FD10-492F-BFB8-C63AC838283A

Q30407860-3587BF7C-A390-4FED-AF7E-287B9D2A4DBA

Q30407860-5C8D14B9-461D-4026-A05D-3638A36140C6

Q30407860-72E2556F-16B1-4771-B7A0-F67DC2B9BD30

P577

Q30407860-32C4606B-0318-412B-8C33-0E9A537260AB

P5875

Q30407860-ACA6C8BA-E819-4ED7-9322-D1A66DD65919

P698

Q30407860-9881ECD2-4284-4FEC-B5FA-2A3E0151F444

P932

Q30407860-E1F81B5B-BB83-4375-9C20-C4AC712CB45B

P356

J.JACC.2013.10.050

P1433

Journal of the American College of Cardiology

P1476

Angiotensin-converting enzyme ...... s with chronic kidney disease.

@en

P2093

Evan H Lott

http://www.w3.org/2001/XMLSchema#string

Jennie Z Ma

http://www.w3.org/2001/XMLSchema#string

Jun Ling Lu

http://www.w3.org/2001/XMLSchema#string

Sandra M Malakauskas

http://www.w3.org/2001/XMLSchema#string

P2860

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease

A new equation to estimate glomerular filtration rate

Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study

The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis

Charlson comorbidity score is a strong predictor of mortality in hemodialysis patients

Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure.

P304

650-658

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACC.2013.10.050

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

63

http://www.w3.org/2001/XMLSchema#string

P50

Miklos Z Molnar

Csaba P. Kovesdy

L. Darryl Quarles

Kamyar Kalantar-Zadeh

P577

2013-11-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259131160

http://www.w3.org/2001/XMLSchema#string

P698

24269363

http://www.w3.org/2001/XMLSchema#string

P932

3944089

http://www.w3.org/2001/XMLSchema#string